Search research articles
Contact Us
Filters
Showing results (431-440 of 504) with videos related to
Page
of 51
Sort By:
Blood
|
August 15, 2013
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
Stephanie Beurlet, Nader Omidvar, Petra Gorombei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
Hagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood Advances
|
November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Ghayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
Blood
|
November 20, 2014
Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation
Andreas Reinisch, Nathalie Etchart, Daniel Thomas, et al.
Hemasphere
|
February 24, 2021
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
Peter Valent, Alberto Orfao, Stefan Kubicek, et al.
American Journal of Hematology
|
October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Nicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
Haematologica
|
April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2015
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff, Kevin R Kelly, Karen Yee, et al.
Blood
|
December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumab
Yasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Page
of 51
Search research articles
Search
Showing results (431-440 of 504) with videos related to
Sort By:
Page
of 51
Blood
|
August 15, 2013
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
Stephanie Beurlet, Nader Omidvar, Petra Gorombei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
Hagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood Advances
|
November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Ghayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
Blood
|
November 20, 2014
Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation
Andreas Reinisch, Nathalie Etchart, Daniel Thomas, et al.
Hemasphere
|
February 24, 2021
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
Peter Valent, Alberto Orfao, Stefan Kubicek, et al.
American Journal of Hematology
|
October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Nicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
Haematologica
|
April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2015
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff, Kevin R Kelly, Karen Yee, et al.
Blood
|
December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumab
Yasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Page
of 51